CD20 drugs for Follicular Lymphoma
4 tracked CD20 drugs in the Follicular Lymphoma race. The class explanation lives on the CD20 page; the full indication pipeline across every mechanism is on the Follicular Lymphoma page.
3 approved / phase 41 Phase 3
Head-to-head evidence: Obinutuzumab vs PF-05280586 · Obinutuzumab beta (Bejescin) vs PF-05280586 · PF-05280586 vs Rituximab